博碩士論文 etd-0718120-210628 詳細資訊


[回到前頁查詢結果 | 重新搜尋]

姓名 陳明楨(Ming-Chen Chen) 電子郵件信箱 E-mail 資料不公開
畢業系所 企業管理學系研究所(Department of Business Management)
畢業學位 博士(Ph.D.) 畢業時期 108學年第2學期
論文名稱(中) 台灣全民健保制度對醫師處方行為與醫療市場影響之實證分析
論文名稱(英) The Empirical Exploration of Physician Prescription Behavior and Pharmaceutical Market Influenced by the Taiwan National Health Insurance Policy
檔案
  • etd-0718120-210628.pdf
  • 本電子全文僅授權使用者為學術研究之目的,進行個人非營利性質之檢索、閱讀、列印。
    請遵守中華民國著作權法之相關規定,切勿任意重製、散佈、改作、轉貼、播送,以免觸法。
    論文使用權限

    紙本論文:3 年後公開 (2023-08-18 公開)

    電子論文:使用者自訂權限:校內 3 年後、校外 3 年後公開

    論文語文/頁數 中文/106
    統計 本論文已被瀏覽 38 次,被下載 0 次
    摘要(中) 長期以來,藥價差對醫師「處方行為」的影響,一直是研究者關切的焦點問題。一般認為,在經濟誘因影響下,醫療提供者為極大化經濟利益,會增加處方藥品量;而此行為不但造成醫療費用上升與醫療資源浪費,更影響百姓的用藥權益與安全、及健康品質的保障。然而,「藥價差」屬於交易雙方之間秘密,不易被觀察出,且處方藥品項目又極為眾多,因此想全面性的以「藥價差」來實證醫師處方藥品行為,難度頗高,故過去少有研究從事此類分析。
       回顧先進OECD國家之藥品醫療市場制度,除美國為自由交易經濟市場外,其他國家之藥品醫療市場皆是由政府高度介入,而由於各國政府對其藥品與醫療的不同政策與制度,也反應出不同的結果與效應。於本研究,以台灣全民健保制度作為研究個案,以分析台灣全民健保制度的特點,作為本實證研究假設推論的理論基礎。同時,本研究也以台灣全民健保醫療資料庫之門診就醫資料,作為實證樣本,並不限定就醫科別、藥品類別、或藥品製造商,藉以達到本實證研究之內外部效度。
       本研究是以2008年與2010年台灣全民健保醫療資料庫門診就醫資料之「門診處方治療明細檔 (CD檔)」與「門診處方費用明細檔(OO檔)」為樣本,經串檔,以取得每一處方之治療與藥品明細。爾後,再與台灣健保署2009年(第六次藥價調整)與2011年(第七次藥價調整)之藥品價格調整明細表,進行比對,而得以推算出醫師每一處方所開立之「藥品量」與「藥價差」,並再繼予推算、「處方藥價差」與「處方總藥價」等資訊。
       本研究是以類別二元化之羅吉斯迴歸式進行實證研究分析,結果顯示﹕整體而言,西醫醫療機構處方決策行為(無論論量計酬或論件計酬)且有涉及經濟誘因之傾向,但其涉及經濟誘因之傾向,會因為醫療機構權屬別的不同而有差異。於醫院(只能論量計酬)方面,當處方箋具有藥價差、藥品量多時,醫師處方決策行為傾向不願釋出處方箋。於基層診所(可論量計酬或論件計酬)方面,醫師處方決策行為傾向依其自身條件,選擇適宜與有利的方式申請處方藥品費。
    摘要(英) For quite long time, researchers around the world has been investigating the effects of drug price difference on drug and physician’s prescription behavior. The general view is that medical providers, under economic incentives to maximize economic benefits, will increase the prescribe prescription drugs. Such behavior results in rise of medical expenses and the waste of medical resources, further more it affects people’s right and safety of medicine usage, compromise the people’s quality of health. As “drug price difference” is a secret between the buyer and seller that is difficult to observe, and there is a vast amount of prescription drugs. With such difficulties, not much research with full statistical analysis is done using “drug price difference” as key proof for a doctor’s drug prescription behavior.
    Looking at pharmaceutical and medical market of modern OECD countries, except for the free-trading market of U.S.A., the government of all other countries are highly involved to form plan-based markets. In each case, the different policies on drugs and medical system set by various governments also reflect their effects, advantages, and disadvantages. In this study, we use Taiwan National Health Insurance (TNHI) as a research case, and analyze its characteristics as a basis for theoretical and hypothesis inference of the research. At the same time, this study used TNHI medical outpatient database as empirical sample data and without restricting medical department or drug type, or drug manufacturers. This is to conduct a more comprehensive and random test to validate the internal and external validity of this research.
    This study uses prescription treatment detail (CD file) and prescription cost detail (OO file) in 2008 and 2010 TNHI medical outpatient database. After combining the two files, we shall get each prescription’s the detailed information of the detailed information about “drug item”, “drug quantity”, ”drug price (old price before adjustment)”. And after comparing the combined CD-OO data with the sixth (2009) and the seventh (2011) of Taiwan’s Health Insurance Agency’s bi-annual report of the drug price adjustment summary list (new price after adjustment), we can calculate “drug price difference” and extrapolate “prescription drug price difference”, “prescription total drug price”.
    This study uses logistic regression to analyze the physician prescription behavior. The empirical results are the physician prescription behaviors are involved in economic ncentives, whether the payment way of the fee for service and the diagnose with a fixed
    payment in Taiwan’s National Health Insurance. And the effect degree of economic incentive shall be different by the different medical ownerships (public, corporation, private). From hospitals in the payment way of the fee for service only, the physician prescription behaviors are not willing to release the prescription when the prescription has the drug price difference and much of drugs. From clinics in either the diagnose with a fixed payment or the payment way of the fee for service, the physician prescription behaviors are forward to choose the suitable and beneficial ways based on their conditions to apply the out-patient drug fees.
    關鍵字(中)
  • 藥價差、處方箋釋出、論量計酬、論件計酬、權屬別
  • 關鍵字(英)
  • Drug Price Difference, Prescription Release, Fee for Service, Diagnose with a Fixed Payment, Ownership.
  • 論文目次 目  次
    論文審定書……………………………………………………………………………………………………….…..i
    誌 謝…………………………………………………………………………………………………………………..ii
    摘 要…………………………………………………………………………………………………………………..iii
    ABSTRACT……………………………………………………………………………………………………………..iv
    第一章 緒論…………………………………………………………………………………………………………. 1
    1.1 研究背景…………………………………………………………………………………………… 1
    1.2 研究動機…………………………………………………………………………………………… 3
    1.3 研究目的…………………………………………………………………………………………… 6
    1.4 研究流程…………………………………………………………………………………………… 7
    1.5 研究架構........................................................................................................9
    第二章 文獻回顧…………………………………………………………………………………………………. 11
    2.1藥費、價格與數量關係……………………………………………………………..………11
    2.2醫療提供者處方的經濟行為………………………………………….......................12
    2.3給付制度對醫療行為的影響……………………………………………………………… 15
    第三章 國際藥品政策與給付制度簡介…………………………………………………………………17
    3.1澳洲藥品收載及訂價方式簡介……………………………………………………….....18
    3.2英國藥品支付制度簡介……………………………………………………………………….20
    3.3美國醫療保險及藥價制度簡介……………………………………………………………22
        3.4瑞典藥價結構簡介……………………………………………………………………………….24
    3.5加拿大藥品支付制度簡介……………………………………………………………………25
    3.6日本藥品支出制度簡介……………………………………………………………………….27
    3.7韓國藥價制度簡介……………………………………………………………………………….29
    3.8荷蘭藥價制度簡介……………………………………………………………………………….31
    3.9法國藥價結構及定價方式簡介……………………………………………………………31
    3.10德國藥品定價方式簡介…………………………………………………………………….34
    3.11瑞士藥價制度簡介……………………………………………………………………………..36
    第四章 台灣全民健保制度特徵…………………………………………………………………………….41
    4.1醫藥分業雙軌制度……………………………………………………………………………….41
    4.2藥品交易代理人制度……………………………………………………………………………42
    4.3以處方箋作為藥品費給付(憑證)制度…………………………………………………43
    4.4台灣健保藥品訂價制度……………………………………………………………………….43
    4.5健保藥品給付制度的不同……………………………………………………………………45
    第五章 假設推論…………………………………………………………………………………………………….47
    5.1 藥價調整的基本概念………………………………………………………………………….48
    5.2 健保藥價差的辨...……………………………………………………………………………..48
    5.3 本研究實證藥價差之定…………………………………………………………………….49
    5.4 以論量計酬之假設推…………………………………………………………………………49
    5.5 以論件計酬之假設推論……..……………………………………………………………….50
    5.6 實證模型變數因果關係示意圖……..……..……………………………………………51
    第六章 實證方法………………………………………………………………………………………….……….53
    6.1藥價差推算概念………………………………………………………………………………….53
    6.2資料……………………………………………………………………………………………………..54
    6.3樣本……………………………………………………………………………………………………..54
    6.4變數……………………………………………………………………………………………………..55
    6.4.1論量計酬之變數……………………………………………………………………………….55
    6.4.2論件計酬之變數……………………………………………………………………………….57
    6.5實證模型……………………………………………………………………………………………..58
    6.5.1論量計酬實證模型……………………………………………………………………………58
    6.5.2論件計酬實證模型…………………………………………………............................ 59
    第七章 實證結果………………………………………………….......................................................60
    7.1 描述性統計……………………………...................................................................60
    7.1.1 論量計酬方面…………………….....................................................................60
    7.1.2 論件計酬方面…………………….....................................................................63
    7.2 實證結果與分析…………….…….....................................................................65
    7.2.1論量計酬方面…………….…….......................................................................65
    7.2.2論件計酬方面…………….…….......................................................................74
    7.2.3本研究實證結果總結語............................................................................82
    第八章 結論與討論……………………………………………………………………………………………...84
    參考文獻
    中文文獻………………………………………………………………………………………………………………..88
    英文文獻………………………………………………………………………………………………………………..90
    圖目次
    圖1、研究流程圖………………………………………………………………………………………………......8
    圖2、研究架構圖………………………………………………………………………………………………….10
    圖3、論量計酬實證模型變數因果關係示意圖……………………………………………………51
    圖4、論件計酬實證模型變數因果關係示意圖……………………………………………………52
    表目次
    表1、2000年台灣與OECD主要國家藥品支出水準的比較……………………………….20
    表2、2001年至2012年台灣西醫基層診所與醫院門診之處方釋出率………………46
    表3、論量計酬實證變數描述性統計………………….......................................................61
    表4、論量計酬實證樣本描述性統計………………….......................................................61
    表5、不同權屬別醫療機構(含醫院與診所)實證樣本之描述性統..........................62
    表6、論量計酬醫療機構權屬別(醫院與診所)之描述性統計分析..........................63
    表7、論件計酬西醫基層診所實證樣本之描述性統計..............................................64
    表8、論件計酬西醫基層診所實證變數之描述性統計..............................................64
    表9、論量計酬-應變數處方行為與藥品相關變數之關係分析................................67
    表10、論量計酬-應變數處方行為與藥品、醫療機構相關變數之關係分析.........68
    表11、論量計酬-應變數處方行為與藥品、不同權屬別醫療機構之關係分析....73
    表12、論件計酬-應變數是否使用簡表與藥品相關變數之關係分析.....................76
    表13、論件計酬-應變數是否使用簡表與藥品、醫療機構變數之關係分析.........77
    表14、論件計酬-應變數是否使用簡表與藥品、不同醫療機構變數之關係分
        析...........................................................................................................................82
    附錄......................................................................................................................................97
    附表1 2000年至2007年全球OECD國家藥品消費占國民醫療保健支出之比率
    ..............................................................................................................................................97
    參考文獻 考文獻
    中文文獻:
    行政衛生署中央健康保險局(2013)。「國際藥價政策與管理制度讀書會會議資料」。國際藥價政策與管理制度讀書會,2012年9月至2013年4月。
    江君毅、陳欽賢、劉彩卿(2002)。民眾就醫與醫療院所層級﹕Nested Logit 模型下之探討。台灣經濟學年會。
    李玉明(2013)。「加拿大健康保險制度對台灣之省思」。世界比一比,全民健康保險雙月刊 2013年11月號,106期。ISSN:1026-9592。
    何小鳳(2014)。全民健康保險雙月刊。世界比一比。2014年1月號,107期。 ISSN:1026-9592。
    呂育馨 (2006)。總額預算制度下醫院用藥經濟行為研究。碩士論文。世新大學管理學院經濟學系。
    林淑馨(2013)。質性研究:理論與實務。新北:巨流。
    林麗貞、李蜀平(2014)。我國實施醫藥分業為何變成雙軌制。藥學雜誌,30(2)。
    吳敬堂、張香蘭、王文彥、侯毓昌 (2000)。臨床入徑之介入對論病計酬案件影響之初步探討 – 以急性闌尾炎為例。醫院,33,48-53。
    連賢明 (2008)。如何使用健保資料進行經濟研究。經濟論文叢刊,36:1,115-143。
    黃光華、李玉春、黃昱瞳。於醫藥分業對西醫診所門診處方釋出率及影響因素分析。台灣衛誌200;23﹕469-78。)
    許志仁(2003)於「健保藥價政策對公立醫院藥品聯標效益之影響性研究」
    紀駿輝(2013)。美國醫療保險改革及啟示。全民健康保險雙月刊。2014年1月,107期。ISSN:1026-9592
    張樂心(2004)。不同權屬別醫院之經濟行為研究。博士論文。國立台灣大學公共衛生學院衛生政策與管理研究所。
    許芳瑾、鄭萬祥 (1999)。台灣省醫藥推動之研究。藥學雜誌,15,151-6。
    莊世杰、黃維明、林秀美、袁本治( 2004 )。論病例計酬制度對鼻中隔到成形手術病患醫療資源利用之影響 – 以某區域醫院為例。東港安泰醫護雜誌,10(2),97-104。
    莊逸洲、陳怡如、史麗珠、陳理 (1997)。全民健保實施陰道分娩論病計酬制對醫療資源使用方式之影響 – 以某財團法人醫學中心為例。中華衛誌,18,181-8。
    張佳琪、黃文鴻 (2001)。健保制度對全髖及全膝關節置換手術醫療利用情形之影響。台灣衛誌,20,440-50。
    黃達夫 (2003)。〈為台灣生技產業開路〉,《全民健保傳奇 II》,葉金川編著,頁IX-XIII。台北:董氏基金會。)
    黃慶鴻 (2017)。從世界醫藥分業發展看台灣基層西醫診所門內藥局發展與調整之研究。博士論文。國立台北大學生物資源與暨農學院生物產業發展學系。
    陳世雄 (2017)。台灣全民健保藥品支付制度與藥價差之研究。博士論文。國立台北大學企業管理學系。
    陳計良(2008)。「台灣全民健康保險藥價給付費率調降政策在價格管控之影響探討 –以降血壓藥為例之實證研究」。博士論文。國立台灣大學。
    陳昭姿、黃達夫 (2013)。健保藥品政策對於醫院管理與臨床用藥之影響。科技報導,201403-387期。
    陳美美、蔡榮崇、林永順、廖佳怡(2003)。「慢性病連續處方箋釋出模式建立與成效評估」。行政院衛生署九十二年度委託研究計劃:DOH92-NH-1009。中央健保局。
    陳敦源 (2005)。民主與官僚-新制度論的觀點。台北:韋伯文化。
    程馨、謝啟瑞 (2005)。全民健保藥品政策與藥品費用的經濟分析。經社法制論35期。
    楊百文(2014)。醫藥分業法治之研究。國立中正大學法律研究所碩士論文。未出版,嘉義。
    楊宗翰 (2005)。台灣西醫診所設置「門前藥局」因素之分析。國立陽明大學醫務管理研究所碩士論文。未出版,台北。
    葉至誠 (2000)。社會科學概論。台北:揚智文化。
    鄭彥仕 (2010)。以系統動力學方法探討藥價政策對醫療機構績效之研究-以某地區教學醫院為例。碩士論文。國立中山大學醫務管理研究所。
    錢慶文、黃貴三 (2000)。論病計酬制度對住院日數及醫療費用之影響 ﹕以痔瘡切除手術為例。公共衛生,26,303-17。
    譚令蒂、洪乙禎、謝啟瑞 (2007)。「論藥價差」。經濟論文叢刊,35:4,451-76。
    龔佩珍、呂嘉欣、蔡文正(2007)。對基層醫師釋出慢性病連續處方箋之意願及相關因素的研究,台灣衛誌,2007;26(1)﹕26-37。
    英文文獻:
    Abe M. (1985). Japan’s Clinic Physicians and Their Behavior. Social Science and 
    Medicine, 20, 335-340.
    Addis A. and Magrini N. (2002). “New Approaches to Analyzing Prescription Data and Transfer Pharmacoepiological and Evidence-based Reports to Prescribes”. Pharmacoepidemiology and Drug Safety, 11:721-726.
    Anderson GF、Reinhardt UE, Hussey PS and Petrosyan, V. (2003). “It’s the PriceStupid:Why the United States Is So Different from Other Countries”, Health Affairs, 22(3), 89-105.
    Berndt, E.R. (2002). Pharmaceuticals in U.S. health care: determinants of quantity and price. Journal of Economic Perspectives 16, 45-66.
    Bloor K., Maynard A. and Freemantle N. (1996). “Lessons from International Experience in Controlling Pharmaceutical Expenditure I”, British Medical Journal, 312:1469-71.
    Chen B. H., Liu H. W., Huang S. L., et al. (2000). Comparison of appendectomy medical expense and clinical outcome between fee for service and prospective payment system. Kaohsiung J Med sci, 16, 293-8.
    Cheng, Carol and C.-R. Hsieh (2005). ”Economic Analysis of NHI Pharmaceutical Policies and Drug Expenditures”. Socioeconomic Law and Institution Review,35,1-42. 
    Chang, Le-Shin (2004). “Ownership and Hospital Behaviors”. Ph.D. Dissertation,Institute of Health Policy and Management, National Taiwan University。
    Clancy C. M., Hillner B. E. (1989). Physician as gatekeepers-the impact of financial incentive. Archives of Internal Medicine, 149, 917-920.
    Chou Y.J., Yip W.C., Lee C.H., Hunag N., Sun Y.P., Chang H.J. (2003). Impact of Separating Drug Prescribing and Dispensing on Provider Behavior:Taiwan’s Experience. Health Policy & Planing, 18(3):316-29.
    Crawford, Sue E.S. & Ostrom E. (1995). A Grammar of Institutions. The American
    Political Science Review. 89(3), 582-600.
    Danzon P.M., Towse A., 2003). “Differential Pricing fro Pharmaceuticals﹕Reconciling Access, R and D and Patents”, working paper.
    Donaldson C., and Gerard K. (1989). Paying General Practitioner: Shedding Light on the Review of Health Service. Journal of Royal College of General Practitioner, 39, 114-117.
    Douglas Lundin (2000). Moral Hazard in Physician Prescription Behavior. Center for Health Economics, Stockholm School of Economics, Box 6501, SE-113 Stockholm, Sweden.
    Ellison SF, Snyder CM. (2010). Countervailing Power in Whole Sale Pharmaceuticals. JInd Econ. 2012;58(1):32-35.
    Epstein AJ, Johnson SJ. (2012). Physician Response to Finanical Incentives When Choosing Drug to Treat Breast Cancer. Int J Health Care Finance Econ. 2012;12(4):285-302.
    Feldman R., Sloan F. (1989). Reply frp, Feldman and Sloan. J Health Polit Policy Law, 14, 621-5.
    Frank R.G. (2003). “Government Commitment and Regulation of Prescription Drugs”, Health Affairs, 22(3)46-48.
    Frech, H.E.I. (1976). The Property Rights Theory of the Firm︰Empirical Result from a Natutal Experiment. Journal of Political Economy, 84, 143-152.
    Gage, L. S. (1985). Impact on the Public Hospital. Bull.N.Y. Acad.Med., 61, 75-80.
    Galbraith, J. K. (1952). American Capitalism: The Concept of Countervailing Power. Houghton Mifflin, Boston.
    Geddes G. (1992). Dispensing Physicians. British Medical Journal 306, 478.
    Gosden T., Bowler I., Sutton M. (2000). How do General Practitioners Choose their Practice? Preferences for Practice and Job Characteristics. Journal of Health Service & Research Policy, 5(4), 208-13.
    Gravdal J.A., Korhm C., Glasser M. (1991). Payment mechanism and patterns use of medical service: the example of hypertension. Journal of Family Practice, 32(1), 6-70.
    Grytten, J., Dorthe, H., and Laake, P. (1990). Supplier Inducement: Its Effect on Dental Services in Norway. Journal of Health Economics, Vol. 9, pp. 483-491.
    Hadley J. (1979). Physician Participation in Medicaid: Evidence from California. Health Serv Res, 14, 266.
    Hickson G. B., Altemeier W. A., Perrin J. M. (1987). Physician Reimbursement by Salary or Fee-for-service-effect on Physician Practice Behavior in a Randomized Prospective Study. Pediatrics, 80, 344-350.
    Hogan C. Z. (1992). Volume Response to Medicare Overvalued Procedure Fee Cuts.
    Hsiao W.C., Yip W. et al. (1999). Improving Hong Kong’s Health Care System: Why
    and for whom? Special Report #5: Hong Kong Patient Studies Summary Report. Hong Government Printing Department.
    Hyman, D.A.(1998). Hospital Conversions: Fact, Fantasy, and Regulatory Follies. J Corporation Law, 23, 741-778.
    IHEP. An Analysis of Medical Expenditures Covered by Government-Administered 
      Employment-Based Health Insurance. Tokyo: Institute of Health and Economic Policy, 1996.
    Kremer M. (2002). “Pharmaceuticals and the Developing World”, Journal of Economic Perspectives, 16(4)﹕67-90.
    Lai, X.-Y. (2011). The Study of Price Difference of Pharmaceutical Procurement under the
    Rules of National Health Insurance. Master Dissertation, Institute of Law, Soochow
    University.
    Labelle R. J., Stoddart G., Rice T. (1994). A Re-examination of the Meaning and Importance of Supplier-induced Demand. J Health Econ, 13, 347-68.
    Lawrence D. Brown (2003). Comparing Health Systems in Four Countries: Lessons for the United States. American Journal of Public Health, January 2003, Vol 93, No.1.
    Liu, Y.-M., Y.-H. Kao Yang, and C.-R. Hsieh (2009). “Financial Incentives and
    Physicians’ Prescription Decisions on the Choice between Brand-name and Generic
    Drugs: Evidence from Taiwan,” Journal of Health Economics, 28: 2, 341-349.
    Liu, Y.-M., Y.-H. Kao Yang, and C.-R. Hsieh (2011). “ The Determinants of the Doption
    of Pharmaceutical Innovation: Evidence from Taiwan.” Social Science & Medicine.72, 919-927.
    Liu, Y.-M., Y.-H. Kao Yang, and C.-R. Hsieh (2012). “Regulation and Competition in 
      the Taiwanese Pharmaceutical Market under National Health Insurance,”Journal of
    Health Economics, 31: 3, 471-483.
    Lober C. W., Behlmer s. D., Penneys N. S., Shupack J. L., Thiers B. H. (1988). Physician Drug Dispensing. Journal of the American Academy of Dermatology, 19(5 pt 1), 915-9.
    Macarthur D. (1992). Professions at War: a Look at the Uneasy Relationship Between
      Dispensing Physicians and Pharmacists in the UK. Australian Journal of Pharmacy,
      73, 870-871.
    Milgrom, P., & Robert, J. (1992). Economics, Organization and Management. NJ︰Prentice Hall.
    Morgan S.G. & Bare M.L., (2003). “Whether Seniors’Pharmacare﹕Lessons from (and 
      for ) Canada”, Health Affairs, 22(3)﹕49-59.
    Mortan-Jone A., Pringle M. (1993). Prescribing Costs in Dispensing Practices. British
      Medical Journal 306, 1233-1246.
    Nudelman, P.M., & Andrews. L. M. (1996). The “Value Added”of Not-for-profit
    Health Plans.N.Engl. Med., 334, 1057-1059.
    Pattision R.V., Katz H.M. (1983). Investor-owned and Not-for-profit Hospitals: A
      Comparison based on California Data. N Eng J Med, 309, 347-353.
    Pauly (1980). Doctors and Their Workshop: Economic Models of Physician Behavior.
      Chicago, IL: University of Chicago Press.
    Patented Medicine Price Review Board, PMPRB (2002).
    Phelps C. E. (1986). Induced Demand- Can we Ever Know its Extent? J Health Econ, 5,
    355-65.
    Raffter, F.T. (1984). The Case for Investor-owned Hospitals. Hospital and Community
    Psychiatry, 35, 1013-1016.
    Raisa Berlin Deber (2003). Health Care Reform: Lessons From Canada. American Journal
    of Public Health, January 2003, Vol 93, No. 1.
    Rice, T.H. (1983). The Impact of Changing Medicare Reimbursement Rate on
     Physician-Induced Demand. Medical Care, Vol. 21, pp. 803-815.
    Rice, T.H. (1984). Physicians-Induce Demand for Medical Service:New Evidence from
    the Medicare Program. Adv. Health Econ. Health Serv. Res, 5, 129-160.
    Rice, T.H., and Labelle, R.J. (1989). Do Physicians Induce Demand for Medical Service?
     Journal of Health Politics, Policy and Law, Vol. 14, pp. 587-600.
    Richard R. Abood (2010). Pharmacy Practice and the Law, Sudbury. Mass. : Jones and
    Bartlett Publishers 6th. 127.
    Rossiter, L.F., and Wilensky, G.R. (1983). A Reexamination of the Use Physician
     Services: The Role of Physician-Initiated Demand. Inquiry, Vol. 20, pp. 162-172.
    Ryan M., Bond C. (1994). Dispending Physicians and Prescribing Pharmacists: Economic
      Considerations for the UK. Pharmacoeconomic, 5(1), 8-17.
    Schwartz M., Hager M. (1987). Now, One-stop Medicine? Newsweek, p.32.
    Schwartz T.W. (1968). Institutions and the Rising Economic Value of Man. American
      Journal of Agricultural Economics, 50.
    Seo T. (1994). Prescribing and Dispensing of Pharmaceuticals in Japan. Pharmacoeconomics, 6, 95-102.
    Sloan F., Mitchell J., Cromwell F. (1978). Physician Participation in State Medicaid
      Program. J Hum Re, 13(Supple), 211.
    Toshiaki Lizuka (2007). Experts’ Agency Problems: Evidence from the Prescription
    Drug Market in Japan. RAND Journal of Economics, Vol. 38, No. 3, pp. 844-862.
    Ubaldo C.D., Hall N.S., & Le B. (2014). Postmarketing Review of Intravenous
     Acetaminophen Dosing Based on Food and Drug Administration Prescribing Guideline. Pharmacotherapy, 34 Suppl 1, 34S-9S.
    Weisbroad(1975). Hospital Conversions: Fact, Fantasy, and Regulatory Follies. J
      Corporation Law, 23, 741-778.。
    Woojin Chung, Han Joong Kim. (2005). Interest Groups’ Influence over Drug Pricing 
      South Korea. Yonsei Medical Journal, Vol. 46, No. 3, pp. 321-330.
    Ya-Ming Lui. (2019). Understanding Proft of Medical Providers from Prescription Drugs: Evidence from Taiwan.
    Yang B., Bae J. (2000). Reforming Drug Distribution System in Korea Correcting the Economic Incentives. Annual Meeting, Allied Social Science Association. New Orleans.
    口試委員
  • 黃明新 - 召集委員
  • 劉玉皙 - 委員
  • 鄭兆宏 - 委員
  • 黃浩霆 - 委員
  • 佘健源 - 指導教授
  • 王學亮 - 指導教授
  • 口試日期 2020-07-10 繳交日期 2020-08-18

    [回到前頁查詢結果 | 重新搜尋]


    如有任何問題請與論文審查小組聯繫